Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

GFP, expanding its portfolio of secondary antibodies for life science research. GFP is widely used to monitor protein ...

Roche has licensed an antibody-drug conjugate (ADC) designed to treat advanced small-cell lung cancer from China-based Innovent Biologics for $80 million up front and up to $1 billion in milestone ...

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

In this video, Xiuning Le, MD, PhD, discusses the state of the pipeline for developing EGFR-mutated lung cancer treatments.

A recent study has introduced a novel class of antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), a protein overexpressed in pancreatic ductal adenocarcinoma (PDAC), ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...